Vasomotor symptoms and cardiovascular events in postmenopausal women
Emily D. Szmuilowicz,JoAnn E. Manson,Jacques E. Rossouw,Barbara V. Howard,Karen L. Margolis,Nancy Greep,Robert G. Brzyski,Marcia L. Stefanick,Mary Jo O'Sullivan,Chunyuan Wu,Matthew A. Allison,Diederick E. Grobbee,Karen C. Johnson,Judith K. Ockene,Beatriz L. Rodriguez,Gloria E. Sarto,Mara Z. Vitolins,Ellen W. Seely,Ellen W. Seely +18 more
TLDR
Early VMS were not associated with increased CVD risk, and were associated with decreased risk of stroke, total CVD events, and all-cause mortality.Abstract:
Objective
Emerging evidence suggests that women with menopausal vasomotor symptoms (VMS) have increased cardiovascular disease (CVD) risk as measured by surrogate markers. We investigated the relationships between VMS and clinical CVD events and all-cause mortality in the Women's Health Initiative Observational Study (WHI-OS).read more
Citations
More filters
Journal ArticleDOI
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Cynthia A. Stuenkel,Cynthia A. Stuenkel,Susan R. Davis,Anne Gompel,Mary Ann Lumsden,Mary Ann Lumsden,M. Hassan Murad,JoAnn V. Pinkerton,JoAnn V. Pinkerton,Richard J. Santen,Richard J. Santen +10 more
TL;DR: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric and benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause.
Journal ArticleDOI
Menopausal hot flushes and night sweats: Where are we now?
David F. Archer,David W. Sturdee,Rodney Baber,T. J. de Villiers,Amos Pines,Robert Freedman,Anne Gompel,Martha Hickey,Myra S. Hunter,Roger A. Lobo,Mary Ann Lumsden,Alastair H. MacLennan,Pauline M. Maki,Santiago Palacios,Duru Shah,P. Villaseca,Michelle P. Warren +16 more
TL;DR: Hot flushes are caused by changes in the central nervous system associated with estrogen withdrawal and are best treated with estrogen replacement therapy, and Objective monitoring of hot flushes indicates that placebo has little to no effect on their improvement.
Journal ArticleDOI
The Menopause Transition: Signs, Symptoms, and Management Options.
TL;DR: The menopause transition is a disruptive process that can last for over a decade and causes symptoms in a majority of women, so it is important for clinicians to recognize early signs and symptoms of the transition and be prepared to offer treatment to mitigate these symptoms.
Journal ArticleDOI
Vasomotor Symptoms and Insulin Resistance in the Study of Women's Health Across the Nation
Rebecca C. Thurston,Samar R. El Khoudary,Kim Sutton-Tyrrell,Carolyn J. Crandall,Barbara Sternfeld,Hadine Joffe,Ellen B. Gold,Faith Selzer,Karen A. Matthews +8 more
TL;DR: Hot flashes were associated with a higher HOMA index, an estimate of insulin resistance, and to a lesser extent higher glucose, and metabolic factors may be relevant to understanding the link between hot flashes and cardiovascular disease risk.
Journal ArticleDOI
Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis.
Taulant Muka,Clare Oliver-Williams,Verônica Colpani,Verônica Colpani,Setor K Kunutsor,Susmita Chowdhury,Rajiv Chowdhury,Maryam Kavousi,Oscar H. Franco +8 more
TL;DR: Presence of vasomotor symptoms and other menopausal symptoms are generally associated with an increased risk of cardiovascular disease, which is mainly explained by cardiovascular risk factors.
References
More filters
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI
Design of the Women's Health Initiative clinical trial and observational study
Garnet L. Anderson,S. Cummings,L. S. Freedman,C. Furberg,Maureen M. Henderson,Susan R. Johnson,L. Kuller,JoAnn E. Manson,A. Oberman,Ross L. Prentice,Jacques E. Rossouw,L. Finnegan,R. Hiatt,L. Pottern,J. McGowan,C. Clifford,B. Caan,V. Kipnis,B. Ettinger,S. Sidney,G. Bailey,Andrea Z. LaCroix,Anne McTiernan,Deborah J. Bowen,C. Chen,Barbara B. Cochrane,Julie R. Hunt,Alan R. Kristal,Brian J. Lund,Ruth E. Patterson,Jeffrey L. Probstfield,Lesley F. Tinker,Nicole Urban,Ching Yun Wang,Emily White,J. M. Kotchen,S. Shumaker,P. Rautaharju,F. Rautaharju,E. Stein,P. Laskarzewski,P. Steiner,K. Sagar,M. Nevitt,M. Dockrell,T. Fuerst,John H. Himes,M. Stevens,F. Cammarata,S. Lindenfelser,Bruce M. Psaty,D. Siscovick,W. Longstreth,S. Heckbert,S. Wassertheil-Smoller,W. Frishman,Judy Wylie-Rosett,D. Barad,R. Freeman,S. Miller,Jennifer Hays,R. Young,C. Crowley,M. A. DePoe,G. Burke,E. Paskett,L. Wagenknecht,R. Crouse,L. Parsons,T. Kotchen,E. Braunwald,J. Buring,C. Hennekens,J. M. Gaziano,Annlouise R. Assaf,R. C. Carleton,M. Miller,C. Wheeler,A. Hume,M. Pedersen,O. Strickland,M. Huber,V. Porter,Shirley A.A. Beresford,V. Taylor,N. Woods,J. Hsia,V. Barnabei,M. Bovun,Rowan T. Chlebowski,R. Detrano,A. Nelson,J. Heiner,S. Pushkin,B. Valanis,V. Stevens,E. Whitlock,N. Karanja,A. Clark +98 more
TL;DR: The rationale for the interventions being studied in each of the CT components and for the inclusion of the OS component is described, including a brief description of the scientific and logistic complexity of the WHI.
Journal ArticleDOI
Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population
Debra J Lerner,William B. Kannel +1 more
TL;DR: A population-based survey assessed sex-specific patterns of coronary heart disease occurring over a 26-year period of time, finding that among subjects ages 35 to 84 years, men have about twice the total incidence of morbidity and mortality of women.
Journal ArticleDOI
Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause
Jacques E. Rossouw,Ross L. Prentice,JoAnn E. Manson,LieLing Wu,David H. Barad,Vanessa M. Barnabei,Marcia G. Ko,Andrea Z. LaCroix,Karen L. Margolis,Marcia L. Stefanick +9 more
TL;DR: Whether the effects of hormone therapy on risk of cardiovascular disease vary by age or years since menopause began is explored to explore and women who initiated hormone therapy closer toMenopause tended to have reduced CHD risk compared with the increase inCHD risk among women more distant from menopausal symptoms.
Deaths: final data for 2006.
Melonie P. Heron,Donna L. Hoyert,Susan L. Murphy,Jianjiang Xu,Kenneth D. Kochanek,Betzaida Tejada-Vera +5 more
TL;DR: Mortality patterns in 2006, such as the decline in the age-adjusted death rate to a record historical low, were generally consistent with long-term trends, and life expectancy increased in 2006 from 2005.